| Not Yet Recruiting | ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL NCT07342478 | Newave Pharmaceutical Inc | Phase 3 |
| Not Yet Recruiting | Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human NCT07259070 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL NCT07120633 | The Affiliated Hospital of Xuzhou Medical University | N/A |
| Recruiting | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL NCT07108998 | Zulfa Omer | Phase 2 |
| Recruiting | A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868 | University Hospital Tuebingen | Phase 1 |
| Recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Sm NCT06846671 | BeOne Medicines | Phase 3 |
| Active Not Recruiting | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participant NCT06697184 | BeiGene | Phase 1 / Phase 2 |
| Active Not Recruiting | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia NCT06944119 | Tel-Aviv Sourasky Medical Center | — |
| Not Yet Recruiting | The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China NCT06557304 | Peking University People's Hospital | — |
| Not Yet Recruiting | The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China NCT06489184 | Peking University People's Hospital | — |
| Enrolling By Invitation | Real-world Study of Acalabrutinib NCT06767891 | Ruijin Hospital | — |
| Recruiting | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms NCT06506643 | Vector Vitale LLC | Phase 1 / Phase 2 |
| Recruiting | Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia NCT05869279 | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Pa NCT06073821 | BeOne Medicines | Phase 3 |
| Recruiting | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refract NCT05947851 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL NCT05209308 | MEI Pharma, Inc. | Phase 2 |
| Active Not Recruiting | Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) NCT05517265 | iOMEDICO AG | — |
| Recruiting | Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia NCT05246345 | University Hospital, Clermont-Ferrand | — |
| Unknown | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients NCT04640909 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Unknown | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. NCT04923048 | Genor Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocy NCT04806035 | TG Therapeutics, Inc. | Phase 1 |
| Unknown | The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 NCT04746092 | Tel-Aviv Sourasky Medical Center | — |
| Active Not Recruiting | CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With NCT04639362 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Withdrawn | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lym NCT04694560 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia NCT04512105 | University of California, Irvine | Phase 1 |
| Withdrawn | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL NCT03639324 | Virginia Commonwealth University | Phase 1 |
| Terminated | Hypertension Management in Cancer Patients NCT03919214 | Duke University | N/A |
| Recruiting | Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early NCT03868722 | Rigshospitalet, Denmark | Phase 2 / Phase 3 |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leuk NCT04016636 | Mela Osorio Maria Jose | — |
| Terminated | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL NCT03572634 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Completed | Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia NCT05316831 | Region Örebro County | Phase 4 |
| Unknown | Study of the Metabolism in the Lymphatic Niche of CLL NCT05610228 | Centre Hospitalier Universitaire de Nice | — |
| Completed | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and C NCT03524235 | Noah Merin | Phase 1 |
| Active Not Recruiting | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL NCT03283137 | University of Chicago | Phase 1 |
| Completed | Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter NCT03113695 | University of California, San Diego | Phase 1 |
| Completed | Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study NCT03231579 | Carevive Systems, Inc. | — |
| Unknown | Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia NCT02828774 | Assuta Medical Center | — |
| Completed | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies NCT02362035 | Acerta Pharma BV | Phase 1 / Phase 2 |
| Unknown | Heavy Light Chain in Chronic Lymphocytic Leukemia NCT02377869 | Bnai Zion Medical Center | — |
| Unknown | A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic L NCT02229422 | University of California, San Diego | Phase 1 / Phase 2 |
| Terminated | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) NCT02046928 | Ångstrom Pharmaceuticals | Phase 2 |
| Unknown | Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients NCT01862445 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Registry of the German CLL Study Group NCT02863692 | German CLL Study Group | — |
| Completed | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL NCT01703364 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 1 / Phase 2 |
| Terminated | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives NCT01532635 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Terminated | Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL NCT01465334 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) NCT01168921 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) NCT01199575 | University of California, San Diego | Phase 2 |
| Completed | Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) NCT01191190 | Januario Castro, M.D. | Phase 2 |
| Completed | Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) NCT01675102 | European Society for Blood and Marrow Transplantation | — |
| Completed | Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) NCT01397916 | Tampere University Hospital | — |
| Completed | A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Distu NCT00792077 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) NCT00628238 | Chronic Lymphocytic Leukemia Research Consortium | Phase 2 |
| Completed | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL NCT00546793 | Gilead Sciences | Phase 1 / Phase 2 |
| Completed | Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older NCT00535873 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of He NCT00533923 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia NCT00021749 | Genta Incorporated | Phase 1 / Phase 2 |
| Completed | Allogeneic Transplantation From Related Haploidentical Donors NCT00185692 | Stanford University | Phase 2 |
| Completed | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders NCT00636909 | Beth Israel Deaconess Medical Center | Phase 2 |